Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics

Drug Metabolism and Disposition

Volumn 38, Issue 9, 2010, Pages 1456-1463

  Oishi, Masayo ^a,b   Chiba, Koji ^b   Malhotra, Bimal ^a   Suwa, Toshio ^b  

^a PFIZER INC   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SINGLE DRUG DOSE; CASE CONTROL STUDY; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

BENZHYDRYL COMPOUNDS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRESOLS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE;

EID: 77955998753     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033407     Document Type: Article

References (22)

1. Bernard S, Neville KA, Nguyen AT, and Flockhart DA (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126-135.
2. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243.
3. Brynne N, Dalén P, Alván G, Bertilsson L, and Gabrielsson J (1998) Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 63:529-539. (Pubitemid 28277274)
4. Clemett D and Jarvis B (2001) Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18:277-304.
5. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
6. Ito K and Houston JB (2004) Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 21:785-792.
7. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
8. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
9. Kubo M, Koue T, Maune H, Fukuda T, and Azuma J (2007) Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 22:358-366.
10. Larsson G, Hallén B, and Nilvebrant L (1999) Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 53:990-998. (Pubitemid 29196317)
11. Malhotra B, Guan Z, Wood N, and Gandelman K (2008) Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 46:556-563.
12. Nilvebrant L (2000) The mechanism of action of tolterodine. Rev Contemp Pharmacother 11:13-27.
13. Olsson B and Szamosi J (2001) Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 40:227-235. (Pubitemid 32324452)
14. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, and Sawada J (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19:83-95.
15. Påhlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 20:91-99.
16. Postlind H, Danielson A, Lindgren A, and Andersson SH (1998) Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 26:289-293.
17. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, and Hiratsuka M (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 36:2460-2467.
18. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, and Li C (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292-1300.
19. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, and Tolterodine Study Group (2001) Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57:414-421. (Pubitemid 32192963)
20. Yamazaki H, Kiyotani K, Tsubuko S, Matsunaga M, Fujieda M, Saito T, Miura J, Kobayashi S, and Kamataki T (2003) Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 18:269-271.
21. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, and Gonzalez FJ (1993) Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263.
22. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689-723.